William Creasman to Survival Analysis
This is a "connection" page, showing publications William Creasman has written about Survival Analysis.
Connection Strength
0.181
-
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecol Oncol. 2021 03; 160(3):660-668.
Score: 0.040
-
The National Cancer Data Base report on early stage invasive vulvar carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1997 Aug 01; 80(3):505-13.
Score: 0.032
-
Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol. 1993 Aug; 11(8):1523-8.
Score: 0.024
-
Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1467-70.
Score: 0.023
-
A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
Score: 0.020
-
Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990 Jun; 37(3):390-5.
Score: 0.019
-
Combined adverse effect of African American race and deep stromal invasion on survival following radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2008 Aug; 199(2):196.e1-7.
Score: 0.017
-
Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990 Feb; 36(2):166-71.
Score: 0.005